MAO Inhibitors: MAO antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. Tricyclic Antidepressants: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents.
Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecules, thereby decreasing urinary excretion. Urinary Acidifying Agents (ammonium chloride, sodium acid phosphate, etc.): Increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.Īdrenergic Blockers: Adrenergic blockers are inhibited by amphetamines.Īlkalinizing agents, Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.): Increase absorption of amphetamines. Interaction :Īcidifying Agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.): Lower absorption of amphetamines.
Tachycardia, palpitations, hypertension, cardiomyopathy (on chronic use), psychosis, dizziness, insomnia, euphoria, restlessness, dysphoria, tremor, headaches, motor and phonic tics exacerbation, Tourette’s syndrome, dryness of mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, changes in libido. ≥6 years: 5 mg/day initially, increase by 5 mg weekly until optimal response.
0 kommentar(er)
